Research
A CD7-targeted AAV variant enables efficient T and NK cell engineering in vivo
Nature · By Lingjuan Hong ·
The Brief
- A Nature Biotechnology article reports an AAV variant targeted to CD7 for engineering T and NK cells in vivo.
- The source summary states that the vector enables efficient T and NK cell engineering in vivo.
Why it matters
It describes a way to deliver genetic engineering to T and NK cells inside the body by targeting a viral vector to CD7, which may inform the development of future cell-based therapies.
Who’s affected
- researchers in gene therapy and vector design
- immunology and cell therapy researchers
- #gene therapy
- #aav vectors
- #t cells
- #nk cells
- #in vivo engineering
Nature Biotechnology, Published online: 16 November 2026; doi:10.1038/s41587-026-03344-5 Adeno-associated virus vectors targeted to CD7 enable T and NK cell engineering in vivo.